
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/937053/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	4.0	579
2	Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Therapeutics and Clinical Risk Management, 2017, Volume 13, 757-777.	0.9	286
3	Randomized, Placebo-Controlled Trials of Antidepressants for Acute Major Depression: Thirty-Year Meta-Analytic Review. Neuropsychopharmacology, 2012, 37, 851-864.	2.8	198
4	Stratified medicine for mental disorders. European Neuropsychopharmacology, 2014, 24, 5-50.	0.3	152
5	Age at onset versus family history and clinical outcomes in 1,665 international bipolarâ€i disorder patients. World Psychiatry, 2012, 11, 40-46.	4.8	138
6	Predominant recurrence polarity among 928 adult international bipolar I disorder patients. Acta Psychiatrica Scandinavica, 2012, 125, 293-302.	2.2	119
7	Psychoeducation in bipolar disorder with a SIMPLe smartphone application: Feasibility, acceptability and satisfaction. Journal of Affective Disorders, 2016, 200, 58-66.	2.0	110
8	Suicidal Risk Factors in Bipolar I and II Disorder Patients. Journal of Clinical Psychiatry, 2012, 73, 778-782.	1.1	81
9	Overview of antidepressant treatment of bipolar depression. International Journal of Neuropsychopharmacology, 2013, 16, 1673-1685.	1.0	70
10	Risk Factors for Antidepressant-Related Switch to Mania. Journal of Clinical Psychiatry, 2012, 73, e271-e276.	1.1	58
11	Self-monitoring and psychoeducation in bipolar patients with a smart-phone application (SIMPLe) project: design, development and studies protocols. BMC Psychiatry, 2015, 15, 52.	1.1	57
12	Morbidity in Depressive Disorders. Psychotherapy and Psychosomatics, 2017, 86, 65-72.	4.0	51
13	Lithium treatment for unipolar major depressive disorder: Systematic review. Journal of Psychopharmacology, 2019, 33, 167-176.	2.0	50
14	Bipolar depression: Clinical correlates of receiving antidepressants. Journal of Affective Disorders, 2012, 139, 89-93.	2.0	48
15	Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. Journal of Psychopharmacology, 2021, 35, 890-900.	2.0	47
16	Direct comparison of tricyclic and serotonin-reuptake inhibitor antidepressants in randomized head-to-head trials in acute major depression: Systematic review and meta-analysis. Journal of Psychopharmacology, 2017, 31, 1184-1189.	2.0	38
17	Risk factors for rapid cycling in bipolar disorder. Bipolar Disorders, 2015, 17, 549-559.	1.1	29
18	Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. Journal of Affective Disorders, 2013, 144, 191-198.	2.0	28

#	Article	IF	CITATIONS
19	Declining efficacy in controlled trials of antidepressants: effects of placebo dropout. International Journal of Neuropsychopharmacology, 2014, 17, 1343-1352.	1.0	28
20	Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. European Neuropsychopharmacology, 2013, 23, 305-316.	0.3	24
21	Origins of Psychiatric Hospitalization in Medieval Spain. Psychiatric Quarterly, 2012, 83, 419-430.	1.1	23
22	Making sense of DSM-5 mania with depressive features. Australian and New Zealand Journal of Psychiatry, 2015, 49, 540-549.	1.3	20
23	Obesity and brain structure in schizophrenia – ENIGMA study in 3021 individuals. Molecular Psychiatry, 2022, 27, 3731-3737.	4.1	17
24	"Is bipolar disorder an endocrine condition?―Glucose abnormalities in bipolar disorder. Acta Psychiatrica Scandinavica, 2014, 129, 73-74.	2.2	16
25	Predictors of functional outcome after a manic episode. Journal of Affective Disorders, 2015, 182, 121-125.	2.0	16
26	Duration of untreated psychosis and acute remission of negative symptoms in a <scp>S</scp> outh <scp>A</scp> merican firstâ€episode psychosis cohort. Microbial Biotechnology, 2017, 11, 77-82.	0.9	14
27	Clinical characterization of rapid cycling bipolar disorder: Association with attention deficit hyperactivity disorder. Journal of Affective Disorders, 2018, 240, 187-192.	2.0	14
28	Imaging Social and Environmental Factors as Modulators of Brain Dysfunction: Time to Focus on Developing Non-Western Societies. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 8-15.	1.1	14
29	Effects of socioeconomic status in cognition of people with schizophrenia: results from a Latin American collaboration network with 1175 subjects. Psychological Medicine, 2022, 52, 2177-2188.	2.7	13
30	Los costos y consumo de recursos sanitarios asociados a episodios manÃacos en la práctica clÃnica diaria: el estudio MANACOR. Revista De PsiquiatrÃa Y Salud Mental, 2015, 8, 55-64.	1.0	12
31	Early treatment resistance in a Latin-American cohort of patients with schizophrenia. Schizophrenia Research, 2018, 199, 380-385.	1.1	12
32	The enduring gap in educational attainment in schizophrenia according to the past 50 years of published research: a systematic review and meta-analysis. Lancet Psychiatry,the, 2022, 9, 565-573.	3.7	12
33	Pharmacological treatment of bipolar depression. Advances in Psychiatric Treatment, 2014, 20, 193-201.	0.6	11
34	Melancholia: does this ancient concept have contemporary utility?. International Review of Psychiatry, 2020, 32, 466-470.	1.4	10
35	Structural brain abnormalities in schizophrenia in adverse environments: examining the effect of poverty and violence in six Latin American cities. British Journal of Psychiatry, 2021, 218, 112-118.	1.7	10
36	Treatment of Narcolepsy Complicated by Psychotic Symptoms. Psychosomatics, 2009, 50, 427-428.	2.5	9

#	Article	IF	CITATIONS
37	Early Medication Discontinuation on Long-term Recovery Outcome in First-Episode Psychosis. JAMA Psychiatry, 2014, 71, 206.	6.0	9
38	e-HCL-32: a useful, valid and user friendly tool in the screening of bipolar II disorder. Comprehensive Psychiatry, 2015, 56, 283-288.	1.5	9
39	Antidepressant responses in direct comparisons of melancholic and non-melancholic depression. Journal of Psychopharmacology, 2020, 34, 1335-1341.	2.0	9
40	The incidence of non-affective psychotic disorders in Chile between 2005 and 2018: results from a national register of over 30 000 cases. Psychological Medicine, 2022, 52, 914-923.	2.7	9
41	Re-analysis of the earliest controlled trials of imipramine. Journal of Affective Disorders, 2013, 147, 451-454.	2.0	7
42	Brain germinoma presenting as a first psychotic episode in an adolescent male. European Child and Adolescent Psychiatry, 2010, 19, 741-742.	2.8	6
43	Predictors of clozapine discontinuation at 2†years in treatment-resistant schizophrenia. Schizophrenia Research, 2021, 235, 102-108.	1.1	6
44	¿DeberÃa considerarse la obesidad un factor limitante para el tratamiento con clozapina?. Revista De PsiquiatrÃa Y Salud Mental, 2013, 6, 75-79.	1.0	5
45	Implementing Psychosocial Evidence-Based Practices in Mental Health: Are We Moving in the Right Direction?. Frontiers in Psychiatry, 2015, 6, 51.	1.3	5
46	High prevalence of metabolic alterations in Latin American patients at initial stages of psychosis. Microbial Biotechnology, 2019, 13, 1382-1388.	0.9	5
47	A 12-month prospective study on the time to hospitalization and clinical management of a cohort of bipolar type I and schizoaffective bipolar patients. European Psychiatry, 2019, 61, 1-8.	0.1	4
48	Pharmacogenetics in Psychiatry: Perceived Value and Opinions in a Chilean Sample of Practitioners. Frontiers in Pharmacology, 2021, 12, 657985.	1.6	4
49	Prodromal phase: Differences in prodromal symptoms, risk factors and markers of vulnerability in first episode psychosis with onset in late adolescence or adulthood. Acta Psychiatrica Scandinavica, 2022, 146, 36-50.	2.2	4
50	Childhood adversity increases risk of psychotic experiences in patients with substance use disorder. Psychiatry Research, 2022, 316, 114733.	1.7	4
51	Olanzapine in Schizophrenia and Affective Disorders. Drug Safety, 2012, 35, 1185-1186.	1.4	3
52	Clozapine and agranulocytosis in Spain: Do we have a safer population? A 5-year haematologic follow-up. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2012, 5, 37-42.	0.2	3
53	Gender, age and geographical representation over the past 50 years of schizophrenia research. Psychiatry Research, 2022, 307, 114279.	1.7	3
54	Should obesity be a limiting factor for clozapine treatment?. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2013, 6, 75-79.	0.2	2

#	Article	IF	CITATIONS
55	Overview of Antidepressant Treatment of Bipolar Depression. Focus (American Psychiatric Publishing), 2015, 13, 102-112.	0.4	2
56	The Authors' Reply. Drug Safety, 2012, 35, 1183-1184.	1.4	2
57	Functional Dysconnectivity in Ventral Striatocortical Systems in 22q11.2 Deletion Syndrome. Schizophrenia Bulletin, 2022, 48, 485-494.	2.3	2
58	Emotional intelligence: a comparison between patients after first episode mania and those suffering from chronic bipolar disorder type I. Psychological Medicine, 2023, 53, 3065-3076.	2.7	2
59	The real world cost and health resource utilization associated to manic episodes: The MANACOR study. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2015, 8, 55-64.	0.2	1
60	Olanzapine in Schizophrenia and Affective Disorders. Drug Safety, 2012, 35, 1185-1186.	1.4	1
61	Depressive symptoms are associated with higher morning plasma cortisol in primary care subjects. Neuroendocrinology Letters, 2018, 39, 288-293.	0.2	1
62	Consent, decisional capacity and guardianship in mental health research. Wellcome Open Research, 0, 7, 183.	0.9	1
63	Remission and functioning after two years undergoing Long-Acting Injectable Risperidone (LAIR) in recent-onset schizophrenia. European Psychiatry, 2011, 26, 1344-1344.	0.1	0
64	Tricyclic and selective serotonin-reuptake-inhibitor antidepressants compared with placebo in randomized trials for acute major depression. Journal of Psychopharmacology, 2017, 31, 1624-1625.	2.0	0
65	T222. EARLY TREATMENT RESISTANCE IN A LATIN-AMERICAN COHORT OF PATIENTS WITH SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S202-S203.	2.3	0
66	F127. GLOBAL RECOVERY IN A FIRST EPISODE PSYCHOSIS PROGRAM IN SOUTH AMERICA. Schizophrenia Bulletin, 2018, 44, S269-S270.	2.3	0
67	S101. CLINICAL FACTORS ASSOCIATED WITH CANNABIS USE IN A CHILEAN SAMPLE OF FIRST EPISODE PSYCHOSIS PATIENTS. Schizophrenia Bulletin, 2018, 44, S364-S364.	2.3	0
68	T67. CASE CONTROL STUDY OF CANNABIS USE IN FIRST EPISODE PSYCHOSIS IN CHILE. Schizophrenia Bulletin, 2019, 45, S230-S230.	2.3	0
69	Brain Network Architecture Intricately Linked to Morphological Abnormalities in Major Psychiatric Disorders. Biological Psychiatry, 2021, 89, S229-S230.	0.7	0
70	Strategies for Improving Randomized Trial Evidence for Treatment of Bipolar Disorder. , 2015, , 599-622.		0
71	T159. STRUCTURAL BRAIN ABNORMALITIES IN SCHIZOPHRENIA IN ADVERSE ENVIRONMENTS: EXAMINING THE EFFECT OF POVERTY AND VIOLENCE IN SIX LATIN AMERICAN CITIES. Schizophrenia Bulletin, 2020, 46, S291-S292.	2.3	0
72	Effects of Socioeconomic Status in Cognition of People with Schizophrenia: Results From a Latin American Collaboration Network with 1175 Subjects - Corrigendum. Psychological Medicine, 2022, , 1-1.	2.7	0